UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease

Transpl Infect Dis. 2014 Apr;16(2):320-3. doi: 10.1111/tid.12200. Epub 2014 Mar 13.

Abstract

We present a case of foscarnet (FOS) resistance arising from a UL54 mutation after a short duration of FOS exposure, which has not been previously described in a stem cell transplant recipient, to our knowledge. We discuss the use of FOS to treat other viral infections and the implications this may have for the development of resistance mutations and treatment of cytomegalovirus disease.

Keywords: E756K mutation; UL54; cytomegalovirus; foscarnet; resistance.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Cidofovir
  • Cytomegalovirus / genetics*
  • Cytomegalovirus Infections / drug therapy*
  • Cytosine / analogs & derivatives
  • Cytosine / therapeutic use
  • DNA-Directed DNA Polymerase / genetics*
  • Drug Resistance, Viral / genetics*
  • Foscarnet / therapeutic use*
  • Ganciclovir / therapeutic use
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Organophosphonates / therapeutic use
  • Viral Proteins / genetics*

Substances

  • Antiviral Agents
  • Organophosphonates
  • UL54 protein, Human herpesvirus 5
  • Viral Proteins
  • Foscarnet
  • Cytosine
  • DNA-Directed DNA Polymerase
  • Cidofovir
  • Ganciclovir